Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
25 studies found for:    Thrombocytopenia | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
1 Recruiting Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Conditions: Thrombocytopenia;   Alloimmune Platelet Refractoriness
Intervention: Drug: Eculizumab
2 Recruiting American Trial Using Tranexamic Acid in Thrombocytopenia
Condition: Thrombocytopenia
Interventions: Drug: Tranexamic Acid;   Drug: Placebo
3 Not yet recruiting Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia
Conditions: Hematologic Malignancies;   Hypoproliferative Thrombocytopenia
Interventions: Device: Mirasol platelets (MIR PLTs);   Device: Reference platelets (REF PLTs)
4 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
5 Recruiting Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates
Condition: Neonatal Thrombocytopenia
Intervention:
6 Recruiting Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Condition: Glioma
Interventions: Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide Phosphate;   Other: Quality-of-Life Assessment;   Drug: Sodium Thiosulfate
7 Recruiting Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Conditions: Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions: Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
8 Recruiting Screening for Hematology Branch Protocols
Conditions: Anemia;   Hematologic Neoplasm;   Neutropenia;   Pancytopenia;   Thrombocytopenia
Intervention:
9 Recruiting BPM31510 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Previously Treated With Bevacizumab
Conditions: Gliosarcoma;   Recurrent Glioblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ubidecarenone Injectable Nanosuspension
10 Recruiting Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Aplastic Anemia;   Head and Neck Neoplasms;   Bone Marrow Failure
Intervention:
11 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
12 Recruiting Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Condition: Severe Aplastic Anemia (SAA)
Intervention: Drug: Eltrombopag
13 Not yet recruiting Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Conditions: Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study
14 Recruiting Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
Conditions: Anemia;   Fatigue;   Fever;   Lymphadenopathy;   Lymphocytosis;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Plasma Cell Myeloma;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Metformin Hydrochloride;   Other: Pharmacological Study;   Drug: Ritonavir
15 Recruiting Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
Condition: Liver Transplantation
Interventions: Biological: Anti-Thymocyte Globulin - Rabbit;   Biological: darTreg Infusion;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Anti-Infective Prophylaxis;   Procedure: Leukapheresis;   Procedure: Blood draws;   Procedure: Liver biopsies;   Procedure: Liver transplantation
16 Recruiting Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin;   Drug: Rituximab;   Drug: Bendamustine
17 Not yet recruiting Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor, Malignant;   Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Interventions: Drug: 90Y-DOTA-3-Tyr-Octreotide;   Drug: 131I-MIBG
18 Recruiting Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
Condition: Dengue
Intervention: Biological: Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)
19 Recruiting Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Radiation: stereotactic body radiation therapy
20 Recruiting Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990
Condition: Wiskott-Aldrich Syndrome
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.